Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Montfermeil – page 56

3 423 clinical trials in Montfermeil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Montfermeil at a glance
3 423
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 423 trials in Montfermeil

Open in trial search

Thermal burn

Recruiting

Study of dexamethasone effectiveness in reducing complications and mortality in patients with severe burns

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Study of glycerol phenylbutyrate (oral liquid) for treatment of fatigue in patients with pyruvate dehydrogenase deficiency

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Glycerol Phenylbutyrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Potassium Chloride
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Neoplasm

Recruiting

Study of ALE.P02 for Adults with Advanced or Metastatic Squamous Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALE.P02
  • Sponsor:Alentis Therapeutics AG

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Institut Gustave Roussy

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib mesylate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Montfermeil

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on acute myocarditis treatment and cardiac arrhythmia management. Research includes evaluation of corticosteroid therapy for improving left ventricular function and investigating preventive measures for premature ventricular complexes.

  • Myocarditis Treatment Optimization
  • Cardiac Function Management
  • Giant Cell Arteritis Studies

These trials aim to enhance treatment outcomes for patients with various cardiac conditions.

02 Respiratory Medicine

Advanced research in severe asthma management, exploring new biological therapies and treatment optimization strategies. Studies focus on comparing different therapeutic approaches for patients with eosinophilic phenotypes.

  • Asthma Biologics Evaluation
  • Treatment Duration Assessment
  • Therapeutic Monitoring

Investigations aim to improve long-term outcomes for patients with severe respiratory conditions.

03 Inflammatory Conditions

Comprehensive studies examining treatments for ulcerative colitis, sarcoidosis, and inflammatory eye conditions. Research includes innovative monitoring approaches and medication optimization.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Treatment Strategies

Focus on improving patient outcomes through targeted therapies and personalized treatment approaches.

04 Rheumatology and Joint Health

Investigating innovative treatments for knee osteoarthritis and gout, particularly in patients with complex medical conditions. Studies explore new interventional procedures and medication alternatives.

  • Joint Disease Management
  • Pain Control Studies
  • Minimally Invasive Treatments

Research aims to enhance quality of life for patients with chronic joint conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.